The Chemours CompanyCCNYSE

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating

Hold

17 analysts·Moderate coverage

35%

Rating Distribution

Strong Buy

00%

Buy

635%

Hold

1059%

Sell

16%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 31% higher.

Bear Case

$18.00

+20%

Consensus

$19.60

+31%

Bull Case

$21.00

+40%

Price Range17 analysts

Low

Consensus

High

$18.00

$21.00

Current Target

Current Price

$14.99

Upside to Target

$4.61

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$1.74(5 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+4.79%

EPS+35.93%

FY2028

Rev+5.12%

EPS+32.77%

Earnings Surprises

Beat rate:58%(7/12 quarters)

Avg surprise:-62.6%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 21, 2026Truist Financial

Chemours price target raised to $21 from $18 at Truist

Target:$21.00

+37.6%from $15.26

Jan 19, 2026BMO Capital

Chemours price target raised to $20 from $18 at BMO Capital

Target:$20.00

+28.1%from $15.61

Jan 16, 2026RBC Capital

Chemours price target raised to $18 from $16 at RBC Capital

Target:$18.00

+9.6%from $16.42

Nov 10, 2025Truist Financial

Chemours (CC) PT Lowered to $18 at Truist as 'Demand Challenges Persist'

Target:$18.00

+39.5%from $12.90

Oct 16, 2025Mizuho Securities

Chemours price target lowered to $18 from $19 at Mizuho

Target:$18.00

+24.8%from $14.42

Oct 14, 2025RBC Capital

Chemours price target raised to $19 from $15 at RBC Capital

Target:$19.00

+41.4%from $13.44

Oct 6, 2025UBS

Chemours price target raised to $21 from $17 at UBS

Target:$21.00

+31.7%from $15.94

Sep 23, 2025Mizuho Securities

Chemours price target raised to $19 from $16 at Mizuho

Target:$19.00

+11.6%from $17.02

May 7, 2025UBS

Chemours price target lowered to $17 from $18 at UBS

Target:$17.00

+40.5%from $12.10

Apr 15, 2025Mizuho Securities

Chemours price target lowered to $15 from $19 at Mizuho

Target:$15.00

+33.0%from $11.28

Oct 11, 2024RBC Capital

Chemours price target lowered to $28 from $35 at RBC Capital

Target:$28.00

+41.6%from $19.78

Oct 7, 2024BMO Capital

Chemours price target raised to $32 from $30 at BMO Capital

Target:$32.00

+63.5%from $19.57

Aug 6, 2024BMO Capital

Chemours (CC) PT Lowered to $30 at BMO Capital

Target:$30.00

+59.8%from $18.77

Jun 7, 2024Mizuho Securities

Chemours initiated with a Neutral at Mizuho

Target:$25.00

+4.6%from $23.90

May 29, 2024UBS

Box, Inc. (BOX) PT Lowered to $31 at UBS

Target:$31.00

+16.3%from $26.65

Apr 9, 2024BMO Capital

BMO Capital Upgrades Chemours (CC) to Outperform

Target:$34.00

+25.7%from $27.05

Apr 1, 2024UBS

Chemours price target raised to $28 from $21 at UBS

Target:$28.00

-2.6%from $28.74

Apr 1, 2024CFRA

Chemours (CC) PT Raised to $18 at CFRA

Target:$18.00

-37.4%from $28.74

Mar 13, 2024D.A. Davidson

Nature's Sunshine Products (NATR) PT Raised to $24 at DA Davidson

Target:$24.00

-10.6%from $26.84

Dec 1, 2023RBC Capital

Analyst Boosts This Manufacturer Stock To Outperform, Ups Price Target By Over 40%

Target:$40.00

+35.5%from $29.53

Oct 30, 2023Morgan Stanley

Check Out 3 Materials Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts

Target:$33.00

+39.9%from $23.58

Jan 10, 2023RBC Capital

Chemours downgraded to Sector Perform from Outperform at RBC Capital

Target:$33.00

+1.4%from $32.55

May 4, 2022RBC Capital

RBC Capital Maintains Outperform on Chemours, Raises Price Target to $48

Target:$48.00

+21.2%from $39.59

May 20, 2021Bank of America Securities

Chemours Can Leverage Its Leadership Position Against A Favorable Backdrop, BofA Says

Target:$42.00

+28.9%from $32.59

May 10, 2021Morgan Stanley

Chemours (CC) PT Raised to $35 at Morgan Stanley

Target:$35.00

+5.8%from $33.08

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance